Intellia Therapeutics' (NTLA) Sell (D-) Rating Reaffirmed at Weiss Ratings

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report)'s stock had its "sell (d-)" rating reiterated by investment analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

A number of other equities research analysts have also recently issued reports on the stock. Citizens Jmp raised shares of Intellia Therapeutics from a "market perform" rating to an "outperform" rating and set a $33.00 target price on the stock in a report on Monday. Chardan Capital dropped their target price on shares of Intellia Therapeutics from $68.00 to $60.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Royal Bank Of Canada dropped their target price on shares of Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. Guggenheim reaffirmed a "buy" rating and issued a $14.00 target price on shares of Intellia Therapeutics in a report on Wednesday, August 13th. Finally, Wells Fargo & Company reaffirmed an "overweight" rating and issued a $45.00 target price (down from $50.00) on shares of Intellia Therapeutics in a report on Friday, August 8th. Thirteen investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $27.95.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA opened at $24.47 on Wednesday. The company's 50-day moving average price is $13.43 and its two-hundred day moving average price is $10.58. Intellia Therapeutics has a one year low of $5.90 and a one year high of $26.46. The stock has a market capitalization of $2.63 billion, a PE ratio of -5.22 and a beta of 2.37.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. The firm had revenue of $14.25 million for the quarter, compared to analysts' expectations of $12.26 million. During the same period in the previous year, the firm posted ($1.52) EPS. The company's revenue for the quarter was up 104.3% on a year-over-year basis. On average, analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 7,462 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total value of $104,617.24. Following the transaction, the executive vice president directly owned 106,062 shares of the company's stock, valued at $1,486,989.24. This represents a 6.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William J. Chase purchased 100,000 shares of the stock in a transaction on Wednesday, August 20th. The stock was bought at an average cost of $10.03 per share, for a total transaction of $1,003,000.00. Following the completion of the acquisition, the director owned 134,693 shares in the company, valued at approximately $1,350,970.79. This trade represents a 288.24% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 9,364 shares of company stock valued at $137,674 in the last three months. 3.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. ARK Investment Management LLC grew its position in shares of Intellia Therapeutics by 3.8% during the 1st quarter. ARK Investment Management LLC now owns 13,011,015 shares of the company's stock worth $92,508,000 after purchasing an additional 474,629 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Intellia Therapeutics by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company's stock worth $76,447,000 after purchasing an additional 561,978 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Intellia Therapeutics by 5.1% during the 2nd quarter. Geode Capital Management LLC now owns 2,606,222 shares of the company's stock worth $24,449,000 after purchasing an additional 126,049 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Intellia Therapeutics by 73.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company's stock worth $8,822,000 after purchasing an additional 396,858 shares in the last quarter. Finally, Armistice Capital LLC grew its position in shares of Intellia Therapeutics by 78.6% during the 2nd quarter. Armistice Capital LLC now owns 650,000 shares of the company's stock worth $6,097,000 after purchasing an additional 286,000 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.